Peptides DB
Research-centric peptide and protocol reference hub
Study 33 of 33Survodutide (BI 456906) literatureJournal of multidisciplinary healthcare · Review2026

Visceral and Ectopic Fat Remodeling with Incretin-Based Therapies in Type 2 Diabetes: Human Imaging Evidence.

Incretin-based therapies may alter fat distribution in type 2 diabetes, but the clinical implications of these changes need further investigation.

Read at Journal of multidisciplinary healthcareAdd to compare

Where it sits

this study against the rest of the survodutide (bi 456906) corpus
4
Preclinical
10
Observational
3
Open-label
11
Randomised
5
Reviews · this one

Summary and findings

This narrative review examines human imaging evidence regarding adipose tissue and ectopic lipid distribution changes during treatment with incretin-based therapies in adults with type 2 diabetes. The review highlights findings related to hepatic fat, visceral fat reduction, and the effects of various receptor agonists, including survodutide. The study aims to connect depot responses to overall weight loss and organ outcomes.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2026

Abstract

The authors’ words, as Journal of multidisciplinary healthcare supplied them

Incretin-based therapies change the distribution of adipose tissue and ectopic lipid during weight loss. This narrative review examines human imaging evidence across abdominal, hepatic, pancreatic, cardiac and skeletal-muscle fat during treatment with selective glucagon-like peptide-1 (GLP-1) receptor agonists and dual- and triple-receptor agonists. Adults with type 2 diabetes are the primary population; findings from mixed diabetes populations and obesity-related disorders are identified separately. The central question is how depot responses relate to overall weight loss and organ outcomes. Hepatic fat has the most mature evidence, and visceral-fat reduction is supported across multiple studies. Tirzepatide provides the most extensive linked multi-depot imaging dataset, while recent survodutide findings extend GLP-1/glucagon imaging evidence to abdominal fat in obesity without diabetes. Cardiac and skeletal-muscle studies extend assessment to tissue composition and ventricular remodeling; pancreatic, renal sinus and other perivascular responses remain exploratory. Imaging modality, anatomical coverage, segmentation and endpoint definition vary across studies, and receptor comparisons are uneven in their populations, comparators and depots assessed. Remodeling is predominantly weight-associated, with selected studies identifying disproportionate hepatic or visceral responses. Imaging can connect these responses to the organ phenotype of interest: hepatic disease activity, cardiac structure or muscle composition. The next step is to test whether repeated depot measurements improve prediction of functional and clinical outcomes beyond routine weight and metabolic assessment.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Survodutide (BI 456906) corpus

AGLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.Digestive diseases (Basel, Switzerland) · 2023 · n=673 · RR 2.98 for MASH resolution without worsening of fibrosis; 95% CI 2.09-4.24; k=2.reviewACardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2024 · n=5530 · Hazard ratio for primary endpoint was 0.89 (95% CI 0.67-1.18; p<0.0001 for non-inferiority).HumanASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2023 · n=752 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2.HumanASurvodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.Contemporary clinical trials · 2026 · 18.7% body-weight reduction at 46 weeks.reviewCNephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.Diabetes, obesity & metabolism · 2026 · Not reported in abstract.AnimalASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2Human